Form 4: Opus Genetics CEO Corrects Shareholding After Over-Withholding Error

Opus Genetics CEO, George Magrath, received 6,200 shares to correct an over-withholding error from a previous vesting of restricted stock units.

Summary

• Opus Genetics CEO, George Magrath, received 6,200 shares of common stock on December 23, 2024.
• These shares were issued to correct an error where shares were inadvertently over-withheld on November 1, 2024, during the vesting of restricted stock units.
• Following this transaction, Mr. Magrath's total direct holdings amount to 499,150 shares.

Sentiment

Score: 7

Explanation: The document reflects a routine correction of an administrative error. While an error occurred, the prompt correction is a positive sign of internal controls. Overall, the sentiment is neutral to slightly positive.

Positives

• The company has corrected an error in share allocation, ensuring accurate reporting of holdings.
• The correction of the over-withholding demonstrates attention to detail in equity management.

Negatives

• An over-withholding error occurred during the vesting of restricted stock units, requiring a correction.

Risks

• Errors in share allocation, even if corrected, can raise concerns about internal controls.
• Such errors could potentially lead to compliance issues if not handled properly.

Industry Context

This is a routine filing related to executive compensation and share ownership, common in publicly traded companies. It does not indicate any broader industry trends.

Comparison to Industry Standards

• The correction of share allocation errors is a standard practice in corporate governance.
• Many companies use restricted stock units as part of executive compensation packages, and errors in vesting can occur.
• The prompt correction of the error is in line with best practices for public companies.

Stakeholder Impact

• The correction of the share allocation error ensures accurate reporting to shareholders.
• The prompt action may reassure stakeholders about the company's internal controls.

Key Dates

Keywords

Opus Genetics, George Magrath, shareholding, SEC Form 4, restricted stock units, over-withholding, equity compensation